AiCuris is meeting the needs of the growing population of immunocompromised people who require precise therapies to effectively treat infection. Our flagship product, PREVYMIS, marketed by our partner MSD, treats CMV in a defined group of transplant recipients. Our pivotal phase 3 candidate Pritelivir is designed to address recurrent and resistant HSV infections in a broad population of patients with weakened immune systems. For immunocompromised people, an otherwise manageable infection can mean life or death. AiCuris, with its expertise and growing pipeline, is committed to providing therapeutic solutions for them now and in the future.
Company Details
- Employees
- 76
- Founded
- -
- Address
- Friedrich-Ebert-Strasse 475, Building 302,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.aicuris.com
- HQ
- Wuppertal, NRW
Aicuris Anti-Infective Cures Ag Questions
Aicuris Anti-Infective Cures Ag's website is http://www.aicuris.com
Aicuris Anti-Infective Cures Ag's LinkedIn profile is https://www.linkedin.com/company/aicuris
Aicuris Anti-Infective Cures Ag has
76 employees.
View email and phone details for 76
employees at Aicuris Anti-Infective Cures Ag.
Aicuris Anti-Infective Cures Ag's industry is
Biotechnology Research
Aicuris Anti-Infective Cures Ag's top competitors are
Biontech Se,
Biospring Gmbh,
Atriva Therapeutics Gmbh,
Evotec,
Boehringer Ingelheim,
Qiagen,
Bayer,
Ucb,
Immatics,
Miltenyi Biotec.
Aicuris Anti-Infective Cures Ag's categories are Biotechnology Research
Aicuris Anti-Infective Cures Ag's founding year is 2006
